Center-Authored Papers

Filters: Author is Hughes, Timothy P  [Clear All Filters]
2009
Müller MC, Cortes JE, Kim D-W, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L et al..  2009.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.. Blood. 114(24):4944-53. Abstract
Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL et al..  2009.  Lin28 promotes transformation and is associated with advanced human malignancies.. Nature genetics. 41(7):843-8. Abstract
2010
Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG et al..  2010.  Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).. Blood. 116(19):3758-65. Abstract
2011
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, Hughes TP, Radich JP, Hochhaus A.  2011.  BCR-ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(21):6812-6821. Abstract
Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP et al..  2011.  SHP1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.. Blood. 118(13):3634-44. Abstract
2012
White DL, Radich J, Soverini S, Saunders VA, Frede A, Dang P, Cilloni D, Lin P, Mongay L, Woodman R et al..  2012.  Chronic phase chronic myeloid leukemia patients with low OCT-1 activityrandomised to high-dose imatinib achieve better responses, and lower failure rates, than those randomized to standard-dose.. Haematologica. 97(6):907-914. Abstract
2013
Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A et al..  2013.  Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.. BMC cancer. 13(1):173. Abstract
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F et al..  2013.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.. Blood. 122(6):872-84. Abstract
Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J et al..  2013.  Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.. Haematologica. 98(2):193-200. Abstract
2014
Baccarani M, Druker BJ, Branford S, Kim D-W, Pane F, Mongay L, Mone M, Ortmann C-E, Kantarjian HM, Radich JP et al..  2014.  Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.. International journal of hematology. Abstract
2016
Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ.  2016.  Chronic myeloid leukemia: reminiscences and dreams.. Haematologica. 101(5):541-58. Abstract
2017
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S et al..  2017.  Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.. The New England journal of medicine. 376(10):917-927. Abstract